Archives

2016

2015

2014

2013

2012

2009

2008

2007

2006

2005

2004

2003

2002

2016

Purdue Pharma Canada Joins the NEOMED Institute As an Industrial Partner


MONTREAL, and PICKERING, ON, March 22, 2016 /CNW/ - Purdue Pharma Canada along with the NEOMED Institute, a public-private organization dedicated to drug discovery and the development of therapeutics up to human proof of concept, today announced that Purdue has become an industrial partner and thereby becomes one of the five leading pharmaceutical companies to support NEOMED's efforts to close the gap between great science and life-saving medicines.

As part of this partnership, Dr. Julie Ducharme, Purdue's Vice President, Research and Development, will hold a seat on NEOMED's Scientific Advisory Board (SAB), with Purdue taking part in the selection of projects in NEOMED's portfolio and providing guidance on their progress. The SAB plays an active role in the evaluation of in-licensing opportunities and maximizes the chances of success of each potential drug in NEOMED's pipeline.

Dr. Ducharme brings to NEOMED's SAB nearly 20 years of industry experience in drug discovery and early drug development, with expertise in the fields of drug metabolism, pharmacokinetics, and pharmacodynamics. At Purdue, Dr. Ducharme is responsible for building a robust and successful product pipeline to support Purdue Canada's growth strategy.

"This partnership marks an important milestone in our research efforts within Canada, and furthering the success of potential drug candidates in NEOMED's pipeline aligns well with our research goals at Purdue," said Dr. Ducharme, who earned her BPharm, MSc, and PhD degrees at the Université de Montréal, and held post-doctoral fellowships at McGill University and the Université René-Descartes et Paris-Sud (Paris).

Philippe Walker, Chief Scientific Officer at the NEOMED Institute, said, "NEOMED welcomes the opportunity to build stronger links with Purdue's research team in Canada. Purdue has been an R&D pioneer – with a track record of successfully commercializing innovative formulations of central nervous system stimulants and pain medications in Canada, and we look forward to their valuable contribution in support of our mission."

"This partnership supports Purdue Canada's goal of diversifying our existing portfolio and strengthening our research capabilities through external collaboration," said Dr. Craig Landau, President & CEO of Purdue Pharma Canada. "Importantly, this agreement demonstrates our commitment to advancing Canadian scientific excellence through strategic partnerships."

ABOUT PURDUE PHARMA CANADA

Purdue Pharma (www.purdue.ca) is a research-based pharmaceutical company with its headquarters and manufacturing operations located in Pickering, Ontario. The company is a leader in the research and development of medicines for the treatment of pain and ADHD. Privately held, Purdue Pharma Canada is independently associated with the worldwide Purdue/Napp/Mundipharma group of companies.

For more information, please visit our website: http://www.purdue.ca

ABOUT THE NEOMED INSTITUTE

The NEOMED Institute is a not-for-profit organization whose mission is to create a bridge between basic research and the commercialization of new drugs by providing industrial expertise in drug discovery and development, combined with funding and a favourable ecosystem, to transform innovations into solid therapeutic solutions. NEOMED drives drug discovery activities up to the stage of human proof of concept. The NEOMED Institute has two fully integrated research and development facilities: one in Technoparc Montréal's Saint-Laurent Campus, specializing in small molecule therapeutics, and the other facility, specializing in the development of biologics and vaccines, in Laval. Both facilities function as open-access drug discovery hubs housing independent commercial businesses and providing a dynamic environment that stimulates collaboration, innovation, and creativity.

The NEOMED Institute is jointly funded by the pharmaceutical industry, the Ministère de l'Économie, de la Science et de l'Innovation du Québec, and the Networks of Centres of Excellence (NCE) of Canada.

For more information, please visit our website: www.neomed.ca

2016 

Purdue Pharma Canada announces the appointment of Dr. Julie Ducharme as Vice President, Research and Development

 


PICKERING, ON, Jan. 11, 2016 /CNW/ - Purdue Pharma Canada today announced the appointment of Dr. Julie Ducharme as Vice President, Research and Development.

"Dr. Ducharme is a dynamic leader with a proven track record in clinical research, drug discovery and early drug development both in Canada and internationally." said Dr. Craig Landau, President and CEO of Purdue Pharma. "Her extensive network and her experience in progressing collaborative projects will be key to building a robust product pipeline and to driving Purdue's growth strategy."

Fluently bilingual, Dr. Ducharme brings to Purdue almost 20 years industry experience in drug discovery and early drug development, including 16 years at AstraZeneca, where she held roles of increasing accountability, culminating as the lead for the company's R&D strategy for their analgesia portfolio. Most recently, Dr. Ducharme was General Manager of Human Health Therapeutics at the National Research Council of Canada (NRC). Under her leadership, Human Health Therapeutics became a leading portfolio at NRC, working with biotech firms in the development of biologics, vaccines, and delivery of large molecules to the brain.

An expert in the fields of drug metabolism, pharmacokinetics and pharmacodynamics, Dr. Ducharme has worked in numerous disease areas including analgesia, anesthesia, neuroscience, cancer and infectious disease. She is an adjunct professor of pharmacy at the Université de Montréal and sits on several scientific advisory boards.

Dr. Ducharme earned her BPharm, MSc and PhD degrees at the Université de Montréal, and held post-doctoral fellowships at McGill University and the Université de Paris.

About Purdue Pharma Canada

Purdue Pharma (www.purdue.ca) is a research-based pharmaceutical company with its headquarters and manufacturing operations located in Pickering, Ontario. The company is a leader in the research and development of medicines for the treatment of pain and ADHD. Privately held, Purdue Pharma Canada is independently associated with the worldwide Purdue/Napp/Mundipharma group of companies.

 

2015

Purdue Canada diversifies its portfolio by acquiring Merck's ophthalmology franchise as part of a multiregional agreement led by Mundipharma


Acquisition highlights:

- Acquired portfolio consists of COSOPT®, COSOPT® Preservative-Free, TIMOPTIC®, TIMOPTIC XE®, TIMOPTIC® Preservative Free, TRUSOPT® and TRUSOPT® Preservative Free
- Agreement covers Australia, Canada, Latin America, Middle East, Africa and New Zealand

PICKERING, ON, Dec. 9, 2015 /CNW/ - Purdue Pharma (Canada) today announced Mundipharma Ophthalmology Products completed a multi-regional agreement with Merck, known as MSD outside the United States and Canada, to acquire its ophthalmology portfolio for the treatment of increased ocular pressure caused by open angle glaucoma or ocular hypertension. This multiregional acquisition agreement will give Purdue Canada marketing rights to Merck's ophthalmology portfolio in Canada as part of the Mundipharma Ophthalmology Products Agreement that includes Australia, Latin America, Middle East, Africa and New Zealand. This multiregional agreement was previously announced on December 3, 2015.

This agreement supports Purdue Canada's desire to diversify our existing portfolio and strengthen our ability to grow in Canada," says Craig Landau, president & CEO of Purdue Canada. "We are excited to build on Merck's success with this portfolio and are committed to ensuring the best-in-class quality and access to these trusted products for glaucoma patients in Canada.

Glaucoma is the second most common cause of blindness worldwide. It is estimated that 4.5 million people globally are blind due to glaucomai and that this number will rise to 11.2 million by 2020ii. In Canada, glaucoma is the second most common cause of vision loss in seniors. More than 250,000 Canadians have chronic open-angle glaucoma, the most common form of the diseaseiii.

The acquired portfolio for Canada consists of COSOPT®, COSOPT® Preservative-Free, TIMOPTIC®, TIMOPTIC XE®, TIMOPTIC® Preservative -Free, TRUSOPT® and TRUSOPT® Preservative-Free, which cover the primary treatment methods of open-angle glaucoma. TIMOPTIC® is on the World Health Organization's list of essential medicines, and an important first line therapy. COSOPT® and TRUSOPT® both provide important therapies for patients requiring subsequent treatment. COSOPT®, TIMOPTIC®, TIMOPTIC XE®, and TRUSOPT® are Registered Trademarks.

About Purdue Pharma (Canada)
Purdue Pharma (www.purdue.ca) is a research-based pharmaceutical company with its headquarters and manufacturing operations located in Pickering, Ontario. The company is a leader in the research and development of medicines with a focus in pain and central nervous system disorders.

References:

i World Health Organization data. Available at http://www.who.int/blindness/causes/priority/en/index6.html
ii Quigley et al. Br J Ophthalmol 2006; 90:262-267
iii Canadian National Institute for the Blind (CNIB) data. Available at http://www.cnib.ca/en/your-eyes/eye-conditions/glaucoma/Pages/default.as...

Back to Top

 

2015

Purdue Canada diversifies its portfolio by acquiring Merck's ophthalmology franchise as part of a multiregional agreement led by Mundipharma


Acquisition highlights:

- Acquired portfolio consists of COSOPT®, COSOPT® Preservative-Free, TIMOPTIC®, TIMOPTIC XE®, TIMOPTIC® Preservative Free, TRUSOPT® and TRUSOPT® Preservative Free
- Agreement covers Australia, Canada, Latin America, Middle East, Africa and New Zealand

PICKERING, ON, Dec. 9, 2015 /CNW/ - Purdue Pharma (Canada) today announced Mundipharma Ophthalmology Products completed a multi-regional agreement with Merck, known as MSD outside the United States and Canada, to acquire its ophthalmology portfolio for the treatment of increased ocular pressure caused by open angle glaucoma or ocular hypertension. This multiregional acquisition agreement will give Purdue Canada marketing rights to Merck's ophthalmology portfolio in Canada as part of the Mundipharma Ophthalmology Products Agreement that includes Australia, Latin America, Middle East, Africa and New Zealand. This multiregional agreement was previously announced on December 3, 2015.

This agreement supports Purdue Canada's desire to diversify our existing portfolio and strengthen our ability to grow in Canada," says Craig Landau, president & CEO of Purdue Canada. "We are excited to build on Merck's success with this portfolio and are committed to ensuring the best-in-class quality and access to these trusted products for glaucoma patients in Canada.

Glaucoma is the second most common cause of blindness worldwide. It is estimated that 4.5 million people globally are blind due to glaucomai and that this number will rise to 11.2 million by 2020ii. In Canada, glaucoma is the second most common cause of vision loss in seniors. More than 250,000 Canadians have chronic open-angle glaucoma, the most common form of the diseaseiii.

The acquired portfolio for Canada consists of COSOPT®, COSOPT® Preservative-Free, TIMOPTIC®, TIMOPTIC XE®, TIMOPTIC® Preservative -Free, TRUSOPT® and TRUSOPT® Preservative-Free, which cover the primary treatment methods of open-angle glaucoma. TIMOPTIC® is on the World Health Organization's list of essential medicines, and an important first line therapy. COSOPT® and TRUSOPT® both provide important therapies for patients requiring subsequent treatment. COSOPT®, TIMOPTIC®, TIMOPTIC XE®, and TRUSOPT® are Registered Trademarks.

About Purdue Pharma (Canada)
Purdue Pharma (www.purdue.ca) is a research-based pharmaceutical company with its headquarters and manufacturing operations located in Pickering, Ontario. The company is a leader in the research and development of medicines with a focus in pain and central nervous system disorders.

References:

i World Health Organization data. Available at http://www.who.int/blindness/causes/priority/en/index6.html
ii Quigley et al. Br J Ophthalmol 2006; 90:262-267
iii Canadian National Institute for the Blind (CNIB) data. Available at http://www.cnib.ca/en/your-eyes/eye-conditions/glaucoma/Pages/default.as...

Back to Top

Purdue Pharma Canada announces the appointment of Dr. Rami Batal as Vice President, Business Development

PICKERING, ON, Feb. 4, 2015 /CNW/ - Purdue Pharma Canada today announced the appointment of Dr. Rami Batal as Vice President, Business Development.

Dr. Batal brings to Purdue more than 15 years of experience in business development and opportunity evaluation within the life sciences, most recently serving as Principal and Industry Practice Leader of SHI Consulting, a Toronto based management consultancy firm specializing in life science strategies. "Dr. Batal brings to Purdue a global network as well as expertise across a broad range of therapeutic and disease areas, including pain and central nervous system disorders. His blend of clinical, business and consulting experience in the pharmaceutical sector aligns very well with the company's business strategy and will help drive our vision for growth," said Dr. Craig Landau, President and CEO of Purdue Pharma Canada.

Dr. Batal earned his PhD in Experimental Medicine from McGill University and his MBA from Concordia University. He is a Pharmacist who continues to practice in Ontario and Quebec, and has held an Adjunct Professor and Course-Coordinator position with the Faculty of Pharmacy of the University of Toronto.

About Purdue Pharma Canada

Purdue Pharma (www.purdue.ca) is a research-based pharmaceutical company with its headquarters and manufacturing operations located in Pickering, Ontario. The company is a leader in the research and development of medicines for the treatment of pain. Privately held, Purdue Pharma Canada is independently associated with the worldwide Purdue/Napp/Mundipharma group of companies.

2014

Purdue Pharma Canada announces the appointment of Kelly A. Martin as Vice President, Finance and Chief Financial Officer

PICKERING, ON, October 27, 2014 /CNW/ – Purdue Pharma Canada today announced the appointment of Ms. Kelly Martin as Vice President, Finance and Chief Financial Officer.

Kelly brings 25 years of financial and management experience from her tenure in various executive positions. Most recently, she was Vice President Finance & Logistics at Janssen Inc. (Canada), a division of Johnson & Johnson Inc. Kelly is known for her ability to provide leadership during times of change, with a strong commitment to long-term success.

"Effectively leading the function will require meaningful insight and assessment of potential diversification, as well as prudent management of the financial elements of the business," said Dr. Craig Landau, president and CEO of Purdue Pharma Canada. "With Kelly’s combined leadership and financial expertise within the pharmaceutical industry, she will be instrumental in contributing to the overall success of the company."

Kelly earned a Bachelor of Commerce (B.Comm.) degree from the University of Toronto in 1990. She qualified as a Chartered Professional Accountant in March of 1993.

About Purdue Pharma Canada

Purdue Pharma (www.purdue.ca) is a research-based pharmaceutical company with its headquarters and manufacturing operations located in Pickering, Ontario. The company is a leader in the research and development of medicines for the treatment of pain. Privately held, Purdue Pharma Canada is independently associated with the worldwide Purdue/Napp/Mundipharma group of companies.

2014

Purdue Pharma Canada announces the appointment of Grant D. Perry as Vice President of Corporate and Government Affairs

PICKERING, ON, May 15, 2014 /CNW/ - Purdue Pharma Canada today announced the appointment of Grant Perry to the position of Vice President, Corporate and Government Affairs, effective May 15, 2014. In this role, Mr. Perry will also be responsible for the development and implementation of strategies to ensure appropriate patient access to Purdue's current and future marketed products. Mr. Perry reports to Dr. Craig Landau, President and CEO, and will be a key member of Purdue's executive leadership team.

Mr. Perry comes to Purdue from GlaxoSmithKline (GSK) where he spent the last 15 years, most recently as Vice President, Public Affairs and Reimbursement. He previously held leadership roles within the primary care pharmaceutical and vaccine businesses of GlaxoSmithKline, contributing to the success of the business both in Canada and abroad. Along with his broad experience with GSK, Grant's background includes roles with Industry Canada and the Pharmaceutical Manufacturers Association of Canada (now known as Rx&D).

According to Dr. Landau, "Grant's impressive work in policy, patient advocacy and market access at both the federal and provincial levels has earned him the reputation of being among the top in his field. His many years of experience and proven record of accomplishment will help Purdue pursue new growth opportunities, while solidifying its position as the leading innovative analgesic pharmaceutical company in Canada."

About Purdue Pharma Canada

Purdue Pharma (www.purdue.ca) is a research-based pharmaceutical company with its headquarters and manufacturing operations located in Pickering, Ontario. The company is a leader in the research and development of medicines for the treatment of pain. Privately held, Purdue Pharma Canada is independently associated with the worldwide Purdue/Napp/Mundipharma group of companies.

Back to Top

2014

Purdue Pharma Canada announces the appointment of David A. Pidduck as Vice President of Marketing & Health Solutions

PICKERING, ON, Jan. 27, 2014 /CNW/ - Purdue Pharma Canada today announced the appointment of David A. Pidduck to the position of Vice President, Marketing and Health Solutions, effective January 27, 2014. In this role, Mr. Pidduck will be responsible for leading all sales and marketing activities and will be a key member of Purdue's executive leadership team, reporting to Dr. Craig Landau, President and CEO.

Mr. Pidduck earned his MBA from the Kellogg School of Management and comes to Purdue with many years of commercial experience in the pharmaceutical, drug delivery and device industries. He spent over 25 years at Baxter, most recently as Vice President for Baxter's Medication Delivery business in Europe, based in Zurich, Switzerland. In his career at Baxter, David held multiple executive roles within the corporate and regional businesses, and led several Canadian business units. His experience spans many disciplines, including Sales, Marketing, Finance, Business Development, and Corporate Strategy.

According to Dr. Landau: "David's experience in Canada, the U.S. and Europe will provide valuable business and organizational perspectives, and will help Purdue further its position as the leading innovative analgesic pharmaceutical company in Canada. Further, David will be a key contributor to Purdue's business diversification strategy going forward, in keeping with our goal of bringing health benefits to Canadian patients through innovative products."

About Purdue Pharma Canada

Purdue Pharma (www.purdue.ca) is a research-based pharmaceutical company with its headquarters and manufacturing operations located in Pickering, Ontario. The company is a leader in the research and development of medicines for the treatment of pain. Privately held, Purdue Pharma Canada is independently associated with the worldwide Purdue/Napp/Mundipharma group of companies.

Back to Top

2013

PURDUE PHARMA CANADA ANNOUNCEMENT

September 9, 2013

Purdue Pharma Canada is pleased to announce the appointment of Craig Landau, MD to the position of President and CEO at the beginning of September 2013. Dr. Landau will be taking over from Dr. Cornelia Hentzsch, who successfully led Purdue Canada through a challenging transition from OxyContin® to OxyNEO®. Dr. Hentzsch will become a full-time advisor to the Board of Directors and continue her role as Regional Director for Australia/New Zealand.

Dr. Landau entered the pharmaceutical industry in 1997 and has spent the last 14 years at Purdue Pharma (U.S.), headquartered in Stamford, Connecticut. In his most recent role as Chief Medical Officer and Vice President of R&D Innovation, Clinical and Medical Affairs, he led a number of successful clinical development initiatives resulting in analgesic product registrations in the U.S., Europe, and other regions. Through an R&D Innovation function, Dr. Landau has been responsible for pursuing non-drug based technologies and biomarkers intended to bring additional objectivity to the diagnosis and management of pain and the pain patient. Through April 2013, he played a lead role in the development and approval of reformulated OxyContin, a product recently determined by the U.S. Food and Drug Administration to possess abuse deterrent characteristics.

Dr. Landau earned his BSc degree in Physiology and Anatomy from Cornell University, and his MD degree from Mount Sinai School of Medicine. He completed his Anesthesiology residency at Yale University, with specialty training in chronic pain management, obstetric and peripheral vascular anesthesia. A U.S. Army Veteran, in 2004 he completed a distinguished 12-year career in the U.S. Army Medical Corps, Reserve Component, providing clinical anesthesia and pain management care to soldiers at a combat support hospital in support of American forces in Iraq and Afghanistan.

Back to Top

2012

PURDUE PHARMA CANADA STATEMENT ON GENERIC OXYCONTIN®

November 19, 2012

Purdue Pharma Canada is deeply concerned with today's statement from the federal Minister of Health that she may not act to delay a decision on generic OxyContin.

The Minister states that she has heard from doctors and patients about OxyContin's positive impact on the treatment of severe pain and that the issue of prescription drug abuse is larger than one specific product. We agree. But the Minister's own Scientific Advisory Panel recommended in March 2011 that manufacturers introduce new opioids which are less crushable and less abusable. This is why we introduced OxyNEO®.

The Minister refers to "insufficient proof" to back up claims that OxyNEO, the replacement for OxyContin, is harder to abuse. We disagree. In fact, published data from surveillance studies in the U.S., where OxyNEO has been available for two years, has been submitted on a regular basis and the most recent data submission is still under review by Health Canada.

It shows significant decline in abuse and demand, including a lower street price for the tablets as well as decreases in admissions to addiction treatment and the number of adverse drug reactions reported to poison control centres. There is also evidence of improved safety for patients and their caregivers. We are disappointed that Health Canada has not taken this important evidence into account.

The Minister indicates the law does not permit her to withhold approval. On the contrary, under the Food and Drugs Act, the Minister must be satisfied that any drug, including generics, meets safety and effectiveness standards prior to issuing an approval.

A higher standard has been established with OxyNEO and it is one that should now be applied to all new controlled-release oxycodone products, including generics. As such, we urge the Minister to consider the evidence and require any generic OxyContin to meet those standards in the interest of public and patient safety.

About Purdue Pharma Canada

A research-based pharmaceutical company in Pickering, Ontario, Purdue Pharma Canada (www.purdue.ca) is committed to improving patient health and well-being, by developing innovative medicines and supporting quality education for the safe use of its products.

Back to Top

PURDUE PHARMA CANADA STATEMENT ON THE INTRODUCTION OF OXYNEO AS A REPLACEMENT FOR OXYCONTIN

February 27, 2012

Purdue Pharma has been working with health authorities for almost two years to prepare the way for the introduction of OxyNEO as a replacement for OxyContin across Canada. We are aiming to ensure as smooth a transition as possible, after which OxyContin will be discontinued and replaced with OxyNEO.

OxyNEO tablets provide the pain relief of OxyContin. But OxyNEO tablets have different properties. They have been hardened to reduce the risk of being broken, crushed or chewed. The tablets also become gel-like when in contact with water.

The restrictions to OxyNEO funding being imposed by some provinces are surprising. This product was specifically designed to help discourage misuse and abuse of the medication. Health Canada’s Special Advisory Panel recommended that manufacturers introduce new opioids which are less crushable and less abusable. OxyNEO is the first of such products on the market and paradoxically it now faces significant restrictions for new patients in most provinces. Patients currently being treated with OxyContin will be “grandfathered” for varying periods of time, which means they will be allowed to continue therapy with OxyNEO if their physician decides this is appropriate.

Purdue Canada does not claim that OxyNEO will prevent all tampering for the purpose of drug diversion, misuse and abuse. However, it is a step in the right direction. Purdue Canada supports restrictions for strong opioids in accordance with the Canadian Guideline for Opioid Use for Chronic Pain as well as careful patient selection. But we are deeply concerned that decisions to limit access to OxyNEO will compromise optimal patient care.

About Purdue Pharma Canada

A research-based pharmaceutical company in Pickering, Ontario, Purdue Pharma (Canada) (www.purdue.ca) is committed to improving patient health and well-being, by developing innovative medicines and supporting quality education for the safe use of its products. Purdue is a recognized leader in research and development of products for the treatment of pain. Its portfolio of products also includes medication for the treatment of attention deficit hyperactivity disorder (ADHD), respiratory disease, gastrointestinal disorders and infection control.

Back to Top

2009

UOIT announces $25,000 donation from Purdue Pharma

March 6, 2009
Announcement made during second annual Purdue Pharma Distinguished Lecture OSHAWA, ON. - The University of Ontario Institute of Technology's (UOIT) Faculty of Science hosted its second annual Purdue Pharma Distinguished Lecture on campus yesterday and, in conjunction with the event, Purdue announced it has made a $25,000 donation to create an endowment to support UOIT science students.

The donation, which is being matched by the Ontario Trust for Student Support for a total value of $50,000, will be used toward the creation of an endowment that will generate one $2000 award each year. The Purdue Pharma Award will be given to a student pursuing a Bachelor of Science degree with a specialization in Pharmaceutical Chemistry, with preference given to a student who has completed the requirements for six semesters of the program and is enrolled in fourth year.

"On behalf of all the students in the Faculty of Science, I would like to thank Purdue Pharma for this significant contribution, “said Dr. William Smith, dean of the UOIT Faculty of Science. "This generous donation will help relieve the financial demands experienced by students as they continue to pursue a career in the pharmaceutical chemistry field by providing access to UOIT's technology-enhanced learning environment, state-of-the-art labs and world-class professors."
The lecture was delivered by Dr. Timothy Geary, Tier I Canada Research Chair in Parasite Biotechnology at McGill University. Presenting Why Parasites Matter, Dr. Geary spoke to students and community members on a variety of topics including the effect that parasites have on their hosts and potential therapeutic exploitation.

The Purdue Pharma Distinguished Lecture is designed to expose students and the general public to some of the country's leading experts and researchers as they explore a broad range of research topics related to the health of Canadians.

The support of leading corporations such as Purdue Pharma helps enhance the innovative and exceptional educational experience offered to students at UOIT. In particular, it furthers the Faculty of Science's dedication to creating and sharing scientific knowledge and infusing the thrill of discovery in its students, preparing them for rewarding careers as the next generation of highly skilled scientists and professionals or for post-degree studies and graduate school.

About UOIT

As an innovative university, UOIT delivers a leading-edge learning environment that uniquely combines academic knowledge, research opportunities, hands-on skills and a vibrant student life. UOIT's more than 5,500 students are taught by professors who are experts in their fields from around the world. As Ontario's first laptop-based university, the university offers a diverse array of challenging undergraduate and graduate degree programs through its faculties of Business and Information Technology; Criminology, Justice and Policy Studies; Education; Energy Systems and Nuclear Science; Engineering and Applied Science; Health Sciences; and Science. UOIT's commitment to research excellence has resulted in millions of dollars in grants and awards, including five Canada Research Chairs. To find out more, visit www.uoit.ca or call 905.721.8668.

Purdue Pharma joins forces with the Institute of Neurosciences, Mental Health and Addiction

Institute of Neurosciences, Mental Health and Addiction (INMHA) is pleased to announce a new partnership with Purdue Pharma to conduct research into the non-medical (illicit) use of prescription drugs with psychotropic properties - a growing public health problem in Canada.

Purdue is a research-based pharmaceutical company in Pickering, Ontario dedicated to advancing healthcare through research, education and pharmaceutical innovation. As one of several manufacturers in Canada of controlled prescription medications for the treatment of chronic pain, Purdue is concerned about the misuse and abuse of prescription drugs and is interested in funding the program for an understanding of the current prevalence and nature of prescription drug abuse. Privately held, Purdue Pharma is independently associated with the worldwide Purdue/Napp/Mundipharma group of companies.

Through this collaboration, CIHR will support research that collects and analyzes data on the epidemiology of prescription opioid abuse in Canada as well as research that identifies appropriate and effective interventions to reduce abuse and its adverse consequences.

Back to Top

2008

Purdue Pharma wins CPDN manufacturer of the year award

Purdue Pharma was named the Canadian Pharmaceutical Distribution Network, or CPDN’s 2007-2008 Manufacturer of the Year (MOYA), in recognition of Purdue’s superior performance as a supplier to CPDN member hospitals. Faced with touch competition from more than 20 leading pharmaceutical companies in Canada, Purdue stood out in areas including inventory replenishment, backorder management, pricing information and catalogue maintenance.

“Earning this award demonstrated Purdue’s commitment in achieving supply chain excellence and is a direct result of concerted effort on the part of the Purdue Pharma team,” said Brian Lockwood, Vice President, Finance, Purdue Pharma.

Back to Top

2007

United Way celebrates successful campaign

By Mike Johnston
Oshawa-Whitby-Clarington This Week
Fri 09 Feb 2007

DURHAM -- There were smiles and applause all around as volunteers and supporters of the Ajax-Pickering-Uxbridge United Way celebrated the completion of a successful campaign Thursday night.

Purdue Pharma, a long-time supporter of United Way, also received a Corporate Citizenship Award for its lifetime achievement total of $500,000.

"We have had a very successful year. We are excited about our 2006 campaign achievement and we are thankful to all our supporters for their efforts in helping us reach our goal," noted Edna Klazek, chief executive officer of the United Way.

Read the entire story from The Pickering News Advertiser

Back to Top

Smart Software and Purdue Pharma Canada Receive APICS Technology Partnership Award of Excellence

Denver, Colorado, October 22, 2007 - In a ceremony today at the APICS 2007 International Conference and Exposition in Denver, Colorado, APICS--The Association for Operations Management awarded Smart Software, Inc. and Purdue Pharma Canada the 2007 APICS Technology Partnership Award of Excellence.

The APICS Corporate Awards of Excellence is an annual competition that recognizes companies for significant contributions and performance excellence in the field of operations management. The Technology Partnership Award recognizes a partnership between a technology solutions provider and a corporate customer, where the product noticeably increased the customer's success. Entries are judged on the originality of the solution and the way it was developed, its usefulness to the customer and the ability to deliver results, supplier performance in creatively and effectively solving the customer's problems, and the expected future impact of the technology solution.

Purdue Pharma Canada has been a Smart Software customer for a number of years. In 2005, Purdue Pharma and Smart Software partnered to improve the way the pharmaceutical company did its sales and inventory planning. At that time, Purdue Pharma upgraded its Smart Software forecasting solution to SmartForecasts® Enterprise, Smart's flagship product for demand forecasting, planning and inventory optimization. In addition, Smart and its systems integration consultant, Datamorphics, Inc. of Concord, Mass., worked with Purdue's IT, materials planning, and marketing teams to design a way to interface with Purdue Pharma's new J.D. Edwards ERP system that complied with specific data security requirements while providing improved planning and marketing information through a set of customized business intelligence reports.
After Purdue Pharma went live with the finished SmartForecasts system in June 2006, the company was able to increase service levels and reduce inventory. In addition, Purdue's planning and forecasting process became more efficient because of the special interfaces the integration team designed and built, and Purdue's ability to generate and use important planning information has improved substantially because of the custom reports that were also developed.
"Receiving this award is an important milestone in our long-standing relationship with Smart Software," said John Stewart, President and CEO, of Purdue Pharma Canada. "The project we implemented with them has improved our inventory management and the way we make stocking decisions, as well as improve the efficiency of our operations. SmartForecasts continues to produce outstanding results."

"This project was a true partnership with our valued customer, Purdue Pharma Canada," said Charles Smart, President and CEO of Smart Software. "We're pleased to have been able to work with them to improve their planning operations in a way that has achieved so many positive results. The APICS award is icing on the cake."

SmartForecasts Enterprise is a cross-industry solution for demand forecasting, demand planning, and inventory optimization that utilizes pioneering innovations, such as Smart Software's patented technology for forecasting intermittent, or "slow-moving", demand. This unique technology is being used by scores of companies with service parts operations, as well as capital goods manufacturers in a variety of industries. SmartForecasts also leverages customers' existing IT investments and reduces total cost of ownership by integrating easily with host databases, as well as ERP and SCM systems like Epicor, JD Edwards, and SAP.

Back to Top

2006

Purdue Pharma wins Ajax-Pickering Board of Trade Business Excellence Award for 2006

Purdue Pharma is a leading manufacturer of prescription medicines for the treatment of persistent pain. Its Pickering headquarters include an R&D Formulation Laboratory, manufacturing plant, and administrative offices, employing 288 people. The company has been recognized as one of the “Top 100” employers in Canada, and celebrated its 50th anniversary in June 2006. More...

Back to Top

St. Joseph’s pain clinic receives grant

Dec 7. 2006
London, ON – Pharmaceutical company Purdue Pharma has recently awarded $200,000 in an unrestricted grant to the MD Pain Clinic at St. Joseph’s Hospital. The grant will be used to help shorten wait times and to improve patient outcomes at the clinic.

For over a decade, the pain management program at St. Joseph’s has been providing diagnosis and treatment of chronic non-cancer pain, allowing individuals with persistent pain to receive a treatment program they can follow with the help of their family doctor.

This grant will help support the clinic’s need of an additional psychologist, a primary care physician, a registered nurse, a neuropathic pain fellow and clerical staff. Ultimately the clinic hopes to establish a database of patient demographics, treatments and outcomes that will help secure long-term funding from the Ministry of Health and Long-Term Care
Long-term funding support combined with the funds from Purdue Pharma will help to educate primary care physicians in the proper treatment of chronic pain management, which will eventually lead to improved pain management at the primary care level.

Back to Top

2005

Purdue Pharma's $300,000 donation establishes new ambulatory care services centre:

Patients at Rouge Valley Ajax and Pickering to benefit.

Purdue Pharma's Executive Vice President and General Manager John Stewart expanded health care services in the Rouge Valley Ajax and Pickering area on April 25, 2002 with the donation of $300,000 to create the new Purdue Pharma Ambulatory Care Services Centre.

The donation is part of the Rouge Valley Health System's $34 million Vital Links Campaign to fund the Health System's expansion and redevelopment.

"As a leading research-based pharmaceutical company, we share a common goal with health care practitioners - to better the quality of life for patients," said Mr. Stewart. "We must invest in community-based hospitals to ensure that our community grows stronger as it grows larger."

Noting that more and more patients "are coming through our doors," Bruce Cliff, chief operating officer, Rouge Valley Ajax and Pickering said: "It makes everyone's job so much easier when we have the necessary space and tools to get the job done, and that's what makes the support from the community-and gifts like the one we received today from Purdue Pharma-so vital."

The new Purdue Pharma Ambulatory Care Services Centre will be designed to include a multipurpose clinical area that will house examination, treatment and minor surgical procedure rooms, a medical day care and recovery area, a preadmission unit where patients will be assessed and counseled prior to admission for inpatient surgery and a health education area.


Back to Top

2004

Purdue Pharma supports task force recommendations. - February 12, 2004 :

Toronto, Ontario - February 12, 2004 - The Executive Vice President and General Manager of Purdue Pharma announced today his company is taking a leading role in implementing key recommendations of Newfoundland and Labrador's Task Force on the prevention of abuse of OxyContin® and other opioid analgesics. More...

Back to Top

Purdue Pharma and Mount Sinai Hospital Create Partnership

Toronto, Ontario --- December 2, 2004 - The pharmaceutical company that manufactures OxyContin has partnered with one of Canada's leading hospitals to continue its battle against prescription drug abuse. Purdue Pharma and Toronto's Mount Sinai Hospital have joined forces to establish the Mount Sinai/Purdue Pharma Partnership in Pain and Dependency. More...

Back to Top

2003

Purdue Pharma Receives Award Recognizing Partnership in Palliative Care.

April 25, 2003. Purdue Pharma's Kim Cudhea, Territory Manager for Eastern New Brunswick, received the Champion Award from the New Brunswick Hospice Palliative Care Association (NBHPCA). Dr. Sydney Grant, President of the NBHPCA and Sandy Johnson, Secretary & Communications Chair, presented the award during the association's Annual Meeting and Education Day. Purdue is the first pharmaceutical company to receive the Champion Award, which recognizes individuals, groups and companies for exemplary contributions to hospice palliative care in New Brunswick.

The NBHPCA membership has increased 147% in the last two years resulting in their highest levels of education initiatives. Purdue's support contributes to a quarterly newsletter with a section devoted to case studies in pain management, education meetings, speaker sponsorship and executive planning meetings.

Sandy Johnson honoured Kim Cudhea with recognition for her ongoing work and support with the association. She thanked Kim for her efforts in organizational and planning assistance, fuelled by a passion for better pain management for cancer pain sufferers.

pallitative care

Back to Top

2002

Hospice Heartlights: The Newsletter of Hospice Durham

Thank You to PURDUE PHARMA
April 2002. Thanks to the financial support of Purdue Pharma, we are able to produce and mail our newsletter. We are grateful for their ongoing interest in Hospice Durham. We are able also, through Purdue Pharma, to use this case study, which outlines the current philosophy of pain in our clients. In the Volunteer Training Course we try to give our volunteers the basic knowledge of pain management but this case study of a real person with real pain will help to emphasize our teaching.

Back to Top